Cd86 Costimulation
Cd86 Costimulation - Related Videos
03:35
Flow Cytometry-Based Analysis of Dendritic Cell Activation Using Immune Complexes
0 Views •
2025
This video demonstrates a protocol for assessing the activation of dendritic cells using immunoglobulin G (IgG)-coated tumor cells. Dendritic cells internalize the IgG-coated tumor cells, process the tumor antigens, and present them on the surface through MHC-II molecules, along with the co-expression of the costimulatory molecule CD86. These dendritic cells then undergo MHC-II and CD86-targeted immunostaining and flow cytometry analysis to identify their activation state.
03:47
Generation of Immature, Mature, and Tolerogenic Dendritic Cells from Monocytes
0 Views •
2025
This video demonstrates the generation of immature, mature, and tolerogenic dendritic cells, or DCs, from human monocytes. The incubation of monocytes with growth factors and cytokines leads to the production of immature DCs. In response to immune regulatory molecules, immature DCs differentiate into tolerogenic and mature DCs.
06:09
Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
0 Views •
Cited by 37 •
2016
Immature dendritic cells can be selectively differentiated into tolerogenic or mature dendritic cells to regulate the balance between immunity and tolerance. This work presents a means to generate from immature monocyte derived dendritic cells (moDCs), in vitro tolerogenic and mature moDCs that differ in metabolic phenotypes.
FAQs
CD86 can contribute to either activating or inhibitory regulation depending on which T-cell receptor engages it. CD28 supports T-cell survival, proliferation, and cytokine production, whereas CTLA-4 engagement restrains activation. This opposing receptor balance allows immune responses to support pathogen clearance while limiting excessive inflammation and reducing the risk of autoimmunity.
The T-cell receptor first identifies a specific peptide presented by MHC, establishing antigen recognition. CD86 signaling then helps determine whether that recognition develops into a broader T-cell response. Studying both events together is therefore important because peptide specificity alone does not describe the resulting level of activation, cytokine production, or cellular expansion.
Dendritic cells, macrophages, and B cells can provide CD86 to interacting T cells. Including these cell types helps researchers examine how different antigen-presenting environments influence adaptive immune responses. Their relevance extends across infection and immune regulation studies, where the same CD86-dependent signaling framework may be examined in relation to pathogen clearance, tolerance, or inflammation.
During infection, this pathway helps connect antigen recognition with T-cell survival, proliferation, and cytokine production, supporting adaptive responses directed toward pathogen clearance. At the same time, CTLA-4-mediated restraint can limit excessive activation. Consequently, infection studies often examine CD86 signaling as part of the balance between effective defense and harmful inflammation.
Vaccine research examines this pathway because CD86-dependent signaling can influence whether antigen recognition develops into a productive T-cell response. Its effects on survival, proliferation, and cytokine production are relevant when assessing immune activation after vaccination. The pathway therefore provides a framework for studying how antigen presentation may shape adaptive responses without treating activation as the only outcome.
Investigations can address how immune tolerance is maintained, how excessive activation may contribute to autoimmunity, and how infectious disease responses are regulated. The pathway is also relevant to therapies designed to modulate T-cell activation. Comparing activating CD28 engagement with inhibitory CTLA-4 engagement helps connect cellular signaling to these broader immunological and clinical research questions.